相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
4°C, sealed storage, away from moisture and light
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- CAS号:
1151666-58-8
- 规格:
1 mg
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
FD-1080
CAS No. : 1151666-58-8
MCE 国际站:FD-1080
产品活性:FD-1080 是在 NIR-II 区域中具有激发和发射光的荧光团 (Ex=1064 nm, Em=1080 nm),可用于体内成像。
研究领域:Others
作用靶点:Fluorescent Dye
In Vitro: FD-1080 shows superior photostability under the continuous laser irradiation. The quantum yield of FD-1080 is 0.31%, and can be increased to 5.94% after combining with fetal bovine serum (FBS) to form FD-1080-FBS complexes.
In Vivo: The 1064 nm NIR-II excitation of FD-1080 is demonstrated with the high tissue penetration depth and superior imaging resolution compared to NIR excitation from 650 nm to 980 nm. Deeptissue and high-resolution in vivo imaging for the left hindlimb vasculature, abdomen, and brain vessels was realized, allowing penetration through intact skin, tissue, and skull. FD-1080 also quantifying the respiratory rate based on the dynamic imaging of respiratory craniocaudal motion of the liver for the awake and anaesthetized mouse.
相关产品:MitoSOX Red | BODIPY 493/503 | Nile Red | D-Luciferin potassium | JC-1 | FITC | Propidium Iodide | CFDA-SE | FITC-Dextran (MW 4000) | Dihydroethidium | DiR | Calcein-AM | Thiazolyl Blue | 2-NBDG | DiI | Fluo-4 AM | TMRE | Cy5.5 | Indocyanine green | Acridine Orange hydrochloride | CY5 | BODIPY 581/591 C11 | FM4-64 | CY5-SE | PKH 26 | DiD perchlorate | Diphenylterazine
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验第一作者之一的宋尔卫(Erwei Song)是我们熟知的,他是中山大学附二院的医生,现在哈佛大学医学院血液研究中心Judy Lieberman教授组进行博士后研究。他曾发表用尾静脉快速大剂量法向小鼠体内输注siRNA成功实现耐受抗Fas单抗诱导的暴发性肝坏死。 http://www.nature.com/nbt/journal/v23/n6/abs/nbt1101.html;jsessionid=EFF86FD58B3B57397768DE431AACF68D Nature
.,1997,16(3):5[53]Supelco Application Note 106,1998[54]Supelco Application Note 140,1997[55]Supelco Application Note 110,1997[56]Supelco Application Note 121,1997[57]Supelco Application Note 98,1997[58]Aranda R,Burk R C.J.Chromatogr.A,1998,829:401~406[59]
合用,旨在探索联合用药的药物搭配、剂量、疗程,既要减免副作用,又能有效根除Hp的理想方案。 1 对象和方法 1.1 对象 157例患者接受本治疗前6个月内未接受任何药物治疗,治疗前0~3d内经胃镜和胃粘膜Hp检测,阳性的DU或功能性消化不良(FD)。其中男116例,女41例,年龄19岁~73岁,病程2月龄~20年分组后各组间人数、病例种类、性别、年龄、病程长短方面资料相似(P>0.05,表1)。 表1 三期三联疗法方案 方案 n (男/女
技术资料暂无技术资料 索取技术资料

















